Oncolytics reports data from pelareorep studies

Oncolytics (ONCY) Biotech summarized its biomarker and translational data for pelareorep, the Company’s systemically delivered oncolytic virus. The data support pelareorep’s mechanism of action and further strengthen the unique biological rationale and therapeutic potential for pelareorep as a platform immunotherapeutic. These include its ability to replicate in cancer cells, activate immune pathways, and drive T cell expansion and tumor infiltration in immunotherapy-resistant cancers. The translational research included the analysis of blood and tumor samples from patients in the GOBLET and AWARE-1 studies. Analyses revealed consistent immune activation signatures, including: Upregulation of interferons, CXCL9/10/11, and PD-L1 Conversion of immunologically ‘cold’ tumors into ‘hot’ phenotypes; expansion and mobilization of tumor-infiltrating lymphocyte, or TIL, clones in the blood, which correlates with a reduction in tumor size; modulation of the tumor microenvironment (TME) to enhance responsiveness to immune therapies. The GOBLET study continues to enroll PDAC and anal carcinoma patients, and additional translational data readouts are expected next year. The Company expects these and its other clinical data to support its focused and aggressive regulatory path and serve as the biological foundation for registration-enabled studies in immunotherapy-resistant solid tumors. As regulatory conversations progress throughout the summer, the Company expects to provide an updated clinical timeline before the end of the Q3.